I do remember some comments about the study in addition to comments about the study in Germany.
The Aussies used a very young "control" group so their false positive rate was very low and the resulting specificity was very high. That was even worse than what Radient did in there "control" group where they eliminated anyone with a condition that would have produced a higher than normal fibrin level.
I have never shorted nor intend to have any financial interest in this stock. I am not connected with anyone who trades, shorts or has financial interests in this stock. I only post facts and my opinions. I do not post on IHUB with different aliases.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.